Cost-effectiveness Thresholds Used by Study Authors, 1990-2021.
作者信息
Neumann Peter J, Kim David D
机构信息
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
Department of Medicine, University of Chicago, Chicago, Illinois.
出版信息
JAMA. 2023 Apr 18;329(15):1312-1314. doi: 10.1001/jama.2023.1792.
Abstract
摘要
相似文献
1
Cost-effectiveness Thresholds Used by Study Authors, 1990-2021.1990 - 2021年研究作者使用的成本效益阈值。
JAMA. 2023 Apr 18;329(15):1312-1314. doi: 10.1001/jama.2023.1792.
2
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies.中低收入国家成本效益分析阈值的使用和误用：成本效益分析研究中成本每残疾调整生命年的趋势。
Value Health. 2018 Jul;21(7):759-761. doi: 10.1016/j.jval.2017.12.016. Epub 2018 Feb 21.
3
Economic Benefit of Hand Surgical Efforts in Low- and Middle-Income Countries: A Cost-Benefit Analysis.手外科在中低收入国家的经济效益：成本效益分析。
Plast Reconstr Surg. 2020 Feb;145(2):471-481. doi: 10.1097/PRS.0000000000006470.
4
Evaluating the Economic Impact of Plastic and Reconstructive Surgical Efforts in the Developing World: The ReSurge Experience.评估发展中国家整形和重建外科学努力的经济影响：ReSurge 经验。
Plast Reconstr Surg. 2019 Sep;144(3):485e-493e. doi: 10.1097/PRS.0000000000005984.
5
[Application of cost-effectiveness analysis of health care interventions in developing countries. A case study in Mauritius].[卫生保健干预措施成本效益分析在发展中国家的应用。毛里求斯的案例研究]
Nihon Koshu Eisei Zasshi. 2000 Dec;47(12):1018-28.
6
Cost-effectiveness analysis for clinicians.临床医生的成本效益分析。
BMC Med. 2012 Feb 1;10:10. doi: 10.1186/1741-7015-10-10.
7
Cost-effectiveness of health systems strengthening interventions in improving maternal and child health in low- and middle-income countries: a systematic review.卫生系统强化干预措施在改善中低收入国家母婴健康方面的成本效益：系统评价。
Health Policy Plan. 2018 Mar 1;33(2):283-297. doi: 10.1093/heapol/czx172.
8
Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018.利用国家投资决策来告知全球成本效益阈值：2006-2018 年人乳头瘤病毒疫苗的引入。
Value Health. 2021 Jan;24(1):61-66. doi: 10.1016/j.jval.2020.07.012. Epub 2020 Oct 16.
9
Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.确定实现全民健康覆盖的效率路径：基于预期寿命和卫生支出增长的 174 个国家的成本效益阈值。
Lancet Glob Health. 2023 Jun;11(6):e833-e842. doi: 10.1016/S2214-109X(23)00162-6.
10
Theoretically correct cost-effectiveness analysis.理论上正确的成本效益分析。
Med Decis Making. 1999 Oct-Dec;19(4):381-2; discussion 383-4. doi: 10.1177/0272989X9901900404.
引用本文的文献
1
Cost-Effectiveness of Treatment for Opioid Use Disorder in Pregnancy and Its Impact on Birth Outcomes.孕期阿片类物质使用障碍治疗的成本效益及其对分娩结局的影响。
JAMA Pediatr. 2025 Sep 8. doi: 10.1001/jamapediatrics.2025.3067.
2
Consequences of weight cycling in patients with obesity and the potential impact of high protein diet: a health economic assessment from a US societal perspective.肥胖患者体重循环的后果及高蛋白饮食的潜在影响：从美国社会视角进行的健康经济评估
BMJ Open. 2025 Aug 18;15(8):e101058. doi: 10.1136/bmjopen-2025-101058.
3
From Tragedy To Opportunity: Hospital-based Violence Intervention Programs May Address Root-Cause Health Disparities for Violent Traumatic Injury Patients.从悲剧到机遇：基于医院的暴力干预项目可能解决暴力创伤患者的根本健康差异问题。
J Prim Care Community Health. 2025 Jan-Dec;16:21501319251356386. doi: 10.1177/21501319251356386. Epub 2025 Aug 11.
4
Efficiency in health care: connecting economic evaluations with implementation objectives.医疗保健中的效率：将经济评估与实施目标联系起来。
Implement Sci Commun. 2025 Jul 26;6(1):77. doi: 10.1186/s43058-025-00763-4.
5
Optimizing Timing for Respiratory Syncytial Virus Prevention Interventions for Infants.优化婴儿呼吸道合胞病毒预防干预措施的时机
JAMA Netw Open. 2025 Jul 1;8(7):e2522779. doi: 10.1001/jamanetworkopen.2025.22779.
6
Cost-Utility Analysis of Endovascular Ultrasound Renal Denervation to Treat Resistant Hypertension in the United States.美国血管内超声肾去神经术治疗顽固性高血压的成本效用分析。
J Soc Cardiovasc Angiogr Interv. 2025 Jun 17;4(6):103601. doi: 10.1016/j.jscai.2025.103601. eCollection 2025 Jun.
7
Cost-effectiveness analysis of robotic exoskeleton versus conventional physiotherapy for stroke rehabilitation in Singapore from a health system perspective.从卫生系统角度看，新加坡机器人外骨骼与传统物理治疗用于中风康复的成本效益分析。
BMJ Open. 2025 Jul 7;15(7):e095269. doi: 10.1136/bmjopen-2024-095269.
8
Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older.50岁及以上成年人使用24价肺炎球菌结合疫苗的成本效益和预算影响分析。
Vaccine. 2025 Aug 13;61:127433. doi: 10.1016/j.vaccine.2025.127433. Epub 2025 Jul 1.
9
The Impact of Alteplase Coverage on Health Equity for the Treatment of Ischemic Stroke in the USA: A Distributional Cost-Effectiveness Analysis.阿替普酶覆盖范围对美国缺血性中风治疗健康公平性的影响：一项分布成本效益分析
Appl Health Econ Health Policy. 2025 Jul 1. doi: 10.1007/s40258-025-00985-6.
10
Cost analysis of implementing a community health worker-led weight reduction randomized-controlled trial among prediabetic south asian patients at primary care sites in NYC.在纽约市初级保健机构中，针对南亚糖尿病前期患者开展由社区卫生工作者主导的减肥随机对照试验的成本分析。
Implement Sci. 2025 Jun 2;20(1):26. doi: 10.1186/s13012-025-01439-2.
本文引用的文献
1
Trends in Author-Reported Cost-Effectiveness Thresholds in the United States from 1995 to 2018: Implications for Discount Rates.1995 年至 2018 年美国作者报告的成本效益阈值趋势：对贴现率的影响。
Med Decis Making. 2022 Oct;42(7):885-892. doi: 10.1177/0272989X221097106. Epub 2022 May 7.
2
A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States.美国成本效益分析的健康机会成本阈值。
Ann Intern Med. 2021 Jan;174(1):25-32. doi: 10.7326/M20-1392. Epub 2020 Nov 3.
3
A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis.一种确定成本效益分析中最佳意愿支付的新方法。
Value Health. 2019 Jul;22(7):785-791. doi: 10.1016/j.jval.2019.03.003. Epub 2019 May 17.
4
Cost-Effectiveness Thresholds: the Past, the Present and the Future.成本效益阈值：过去、现在和未来。
Pharmacoeconomics. 2018 May;36(5):509-522. doi: 10.1007/s40273-017-0606-1.
5
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.更新成本效益——每质量调整生命年5万美元阈值令人好奇的韧性。
N Engl J Med. 2014 Aug 28;371(9):796-7. doi: 10.1056/NEJMp1405158.
Zotero 插件